Skip to content

Study · Not a test of the peptide alone · 2008

1 result

MALDI-MS derived prognostic protein markers for resected non-small cell lung cancer.

Xu BJ, Gonzalez AL, Kikuchi T, Yanagisawa K, Massion PP, Wu H, Mason SE, Olson SJ, Shyr Y, Carbone DP, Caprioli RM

Proteomics. Clinical applications10 Sept 2008Cited by 23 (Europe PMC)

PMID21136798 (opens in a new tab)PMCIDPMC3728564 (opens in a new tab)DOI10.1002/prca.200800094 (opens in a new tab)PepBankPUB-21136798
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01HumanNot a test of Thymosin beta-4 (human) aloneObservational studyOther

    In patients with resected non-small cell lung cancer, the combined IHC scores of calmodulin, thymosin beta4 and thymosin beta10 correlated with survival.

    In plain wordsIn people with resected lung cancer, a combined tissue score of three proteins, including thymosin beta4, was linked to survival.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableNSCLC survival and combined IHC score of calmodulin, thymosin beta4 and thymosin beta10
    Study

    n: not reported in source

    Outcome group
    Mortality · Cancer

    Measurements

    P value
    0.004
    combined IHC score vs survival

    Source sentences

    Summary
    The combined IHC scores of calmodulin, thymosin β4, and thymosin β10 were found to be correlated with NSCLC patient survival (p = 0.004).
    1 context sentence
    Summary · context
    Kaplan-Meier analysis was used to assess the mortality risk associated with the prognostic protein IHC-staining intensities.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.